See more : Population Health Investment Co., Inc. (PHICU) Income Statement Analysis – Financial Results
Complete financial analysis of Cytocom, Inc. (CBLI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cytocom, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- NEXE Innovations Inc. (NEXNF) Income Statement Analysis – Financial Results
- ZEUS NORTH AMERICA MINING CORP (ZUUZF) Income Statement Analysis – Financial Results
- Hanatour Japan Co., Ltd. (6561.T) Income Statement Analysis – Financial Results
- Gildan Activewear Inc. (GIL.TO) Income Statement Analysis – Financial Results
- Property For Industry Limited (PFI.NZ) Income Statement Analysis – Financial Results
Cytocom, Inc. (CBLI)
About Cytocom, Inc.
Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. The company is headquartered in Buffalo, New York and currently employs 15 full-time employees. The firm is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 262.94K | 1.11M | 1.14M | 1.95M | 3.52M | 2.71M | 3.70M | 8.49M | 3.57M | 8.79M | 15.33M | 14.35M | 4.71M | 2.02M | 1.71M | 1.14M | 636.34K | 75.00K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 262.94K | 1.11M | 1.14M | 1.95M | 3.52M | 2.71M | 3.70M | 8.49M | 3.57M | 8.79M | 15.33M | 14.35M | 4.71M | 2.02M | 1.71M | 1.14M | 636.34K | 75.00K |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 691.07K | 1.66M | 3.62M | 5.05M | 6.50M | 7.14M | 9.65M | 19.53M | 22.50M | 22.79M | 16.14M | 14.33M | 13.16M | 17.43M | 6.99M | 2.64M | 2.89M | 0.00 |
| General & Administrative | 2.16M | 1.82M | 2.32M | 2.50M | 3.38M | 6.36M | 8.47M | 12.04M | 11.12M | 11.11M | 9.93M | 6.40M | 5.89M | 10.53M | 2.14M | 986.42K | 262.82K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.16M | 1.82M | 2.32M | 2.50M | 3.38M | 6.36M | 8.47M | 12.04M | 11.12M | 11.11M | 9.93M | 6.40M | 5.89M | 10.53M | 2.14M | 986.42K | 262.82K | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.85M | 3.47M | 5.94M | 7.55M | 9.87M | 13.50M | 18.12M | 31.56M | 33.62M | 33.90M | 26.07M | 20.73M | 19.05M | 27.96M | 9.13M | 3.63M | 3.16M | 0.00 |
| Cost & Expenses | 2.85M | 3.47M | 5.94M | 7.55M | 9.87M | 13.50M | 18.12M | 31.56M | 33.62M | 33.90M | 26.07M | 20.73M | 19.05M | 27.96M | 9.13M | 3.63M | 3.16M | 0.00 |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 99.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.96K | 0.00 | 0.00 | 11.20K | 17.99K | 0.00 | 0.00 |
| Depreciation & Amortization | 11.45K | 13.78K | 18.18K | 21.08K | 63.46K | 140.14K | 200.79K | 471.21K | 479.60K | 525.51K | 407.29K | 362.14K | 324.35K | 188.40K | 94.93K | 44.76K | 2.30K | -211.83K |
| EBITDA | -2.39M | -2.63M | -3.59M | -9.69M | -2.60M | -12.40M | 1.83M | -16.79M | -30.05B | -3.49M | 0.00 | -12.46M | -13.70M | 0.00 | -7.12M | -2.32M | -2.52M | -136.83K |
| EBITDA Ratio | -907.81% | -236.50% | -315.75% | -497.10% | -73.77% | -457.79% | 49.43% | -197.83% | -497.23% | -39.68% | -169.32% | -86.87% | -291.18% | -1,328.08% | -416.61% | -204.04% | -396.15% | -182.43% |
| Operating Income | -2.59M | -2.36M | -4.80M | -5.60M | -6.36M | -10.79M | -14.42M | -23.08M | -30.05M | -25.11M | -10.74M | -6.38M | -14.35M | -25.94M | -7.42M | -2.49M | -2.52M | 75.00K |
| Operating Income Ratio | -983.70% | -212.03% | -421.72% | -287.46% | -180.65% | -398.45% | -389.58% | -271.88% | -841.47% | -285.60% | -70.03% | -44.49% | -304.86% | -1,285.18% | -434.26% | -218.45% | -395.93% | 100.00% |
| Total Other Income/Expenses | 148.68K | -333.83K | 1.09M | -4.24M | 3.77M | -2.25M | 14.46M | 2.95M | 7.63M | 19.88M | -16.03M | -6.46M | 414.73K | -2.06M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -2.44M | -2.69M | -3.71M | -9.84M | -2.59M | -13.04M | 35.37K | -20.13M | -22.41M | -5.23M | -26.77M | -12.85M | -13.93M | -28.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -927.15% | -242.02% | -325.73% | -505.18% | -73.61% | -481.68% | 0.96% | -237.15% | -627.74% | -59.49% | -174.61% | -89.55% | -296.04% | -1,387.14% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 148.68K | -333.83K | 1.09M | -4.24M | 3.77M | -2.15M | 14.46M | 2.95M | 7.63M | 19.88M | -16.03M | -6.46M | 414.73K | -2.06M | 11.20K | 17.99K | 0.00 | 211.83K |
| Net Income | -2.40M | -2.65M | -3.61M | -9.71M | -2.66M | -12.64M | 1.63M | -17.26M | -18.23M | -4.01M | -26.37M | -12.83M | -14.03M | -27.00M | -7.22M | -2.39M | -2.52M | -136.83K |
| Net Income Ratio | -912.16% | -237.73% | -317.34% | -498.19% | -75.57% | -466.64% | 44.01% | -203.38% | -510.66% | -45.66% | -171.97% | -89.41% | -298.07% | -1,337.42% | -422.82% | -209.55% | -396.51% | -182.43% |
| EPS | -0.19 | -0.23 | -0.32 | -0.87 | -0.24 | -1.79 | 0.60 | -7.67 | -9.75 | -2.47 | -20.14 | -15.64 | -20.79 | -44.66 | -16.22 | -7.64 | -10.93 | -0.01 |
| EPS Diluted | -0.19 | -0.23 | -0.32 | -0.87 | -0.24 | -1.79 | 0.60 | -7.67 | -9.75 | -2.47 | -20.14 | -15.64 | -20.79 | -44.66 | -16.22 | -7.64 | -10.93 | -0.01 |
| Weighted Avg Shares Out | 12.40M | 11.30M | 11.29M | 11.19M | 10.99M | 7.06M | 2.70M | 2.25M | 1.87M | 1.63M | 1.31M | 820.26K | 674.62K | 604.52K | 445.31K | 312.52K | 230.78K | 15.48M |
| Weighted Avg Shares Out (Dil) | 12.40M | 11.30M | 11.29M | 11.19M | 10.99M | 7.06M | 2.70M | 2.25M | 1.87M | 1.63M | 1.31M | 820.26K | 674.62K | 604.52K | 445.31K | 312.52K | 230.78K | 15.48M |
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.32%
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 2.84%
4 Biotech Stocks Moving On COVID-19 Updates
How The COVID-19 Outbreak Is Benefiting Biotech Investors
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
Diagnosis: Volatility — Every Coronavirus-Related Stock That Was Halted For Trading Today
18 Medical Stocks To Watch Amid The Coronavirus Outbreak
18 Medical Stocks To Watch Amid The Coronavirus Outbreak
30 Stocks Moving in Friday's Pre-Market Session
Source: https://incomestatements.info
Category: Stock Reports